| Title |
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
|---|---|
| Published in |
PharmacoEconomics, December 2018
|
| DOI | 10.1007/s40273-018-0750-2 |
| Pubmed ID | |
| Authors |
Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin, Constantine Alifrangis |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 11% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Bachelor | 4 | 9% |
| Researcher | 4 | 9% |
| Student > Doctoral Student | 3 | 7% |
| Other | 6 | 13% |
| Unknown | 19 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Business, Management and Accounting | 3 | 7% |
| Social Sciences | 3 | 7% |
| Nursing and Health Professions | 2 | 4% |
| Other | 2 | 4% |
| Unknown | 20 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2018.
All research outputs
#18,659,789
of 23,117,738 outputs
Outputs from PharmacoEconomics
#1,661
of 1,868 outputs
Outputs of similar age
#324,752
of 436,720 outputs
Outputs of similar age from PharmacoEconomics
#21
of 28 outputs
Altmetric has tracked 23,117,738 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,868 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,720 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.